Abstract 519P
Background
The phase Ⅲ CASPIAN study established durvalumab (D) plus etoposide with cisplatin or carboplatin (EP) as first-line standard of care (1L SoC) of ES-SCLC. The multicenter, single-arm, phase Ⅲb ORIENTAL study evaluated 1L D+EP in a large, real-world-like patient (pt) cohort in China. Preliminary safety and efficacy results were consistent with CASPIAN. Here we report final results and subgroup analysis.
Methods
Treatment-naïve ES-SCLC pts ≥18 years old with ECOG PS 0–2 received D 1500 mg + EP intravenously every 3 weeks for 4–6 cycles, followed by D monotherapy every 4 weeks until progressive disease or intolerable toxicity. Primary endpoints were immune-mediated adverse events (imAEs) and grade ≥3 AEs. Secondary endpoints included OS, PFS, and tumor response.
Results
166 pts from 32 sites were enrolled by Aug 2021 and 165 received study treatment (median [m] age 65 years; 140 [84.8%] male). At baseline, 6 (3.6%) were ECOG PS 2, 155 (93.9%) were stage Ⅳ, 21 (12.7%) had brain metastases, and 44 (26.7%) had liver metastases. By data cut-off (31 Mar 2023), median cycle number of D was 7 (range 1–25). 92 (55.8%) started subsequent systemic anticancer therapy. 40 (24.2%) reported imAEs (most common [≥5%]: hyperthyroidism [6.1%] and hypothyroidism [6.1%]; grade 1/2 mostly). Grade ≥3 AEs occurred in 82 (49.7%) pts and led to treatment interruption in 24 (14.5%). mOS was 14.8 months (mo) (m follow-up [mFU] 20.5 mo). 118 (71.5%) pts received D maintenance, with mOS of 16.6 mo. 85 (51.5%) pts received >4 EP cycles, with mOS of 17.4 mo (Table). mPFS was 6.3 mo (mFU 8.6 mo). ORR was 76.4%, with 3 (1.8%) complete responses (RECIST 1.1). Table: 519P
N=165 | 95% CI | ||
Any-cause AEs, n (%) | 161 (97.6) | ||
Grade ≥3 AEs, n (%) | 82 (49.7) | ||
imAEs, n (%) | 40 (24.2) | ||
Grade ≥3 imAEs, n (%) | 11 (6.7) | ||
mOS, mo | 14.8 | 13.2–16.0 | |
12-mo OS, % | 60.8 | 52.8–67.9 | |
24-mo OS, % | 26.2 | 17.5–35.6 | |
mPFS, mo | 6.3 | 5.6–6.5 | |
12-mo PFS, % | 17.6 | 12.0–24.1 | |
ORR, % | 76.4 | 69.1–82.6 | |
DCR, % | 89.1 | 83.3–93.4 | |
mDoR, mo | 5.1 | 4.7–5.7 | |
Subgroup analysis | n | mOS, mo | 95% CI |
Received D maintenance | 118 | 16.6 | 15.1–18.8 |
ECOG PS | |||
0–1 | 159 | 15.1 | 13.3–16.1 |
2 | 6 | 9.2 | 6.4–Not Available |
Number of EP cycles | |||
≤4 | 80 | 12.7 | 9.4–15.1 |
>4 | 85 | 17.4 | 14.0–21.7 |
First-line platinum | |||
Cisplatin | 17 | 11.1 | 6.5–18.8 |
Carboplatin | 148 | 15.2 | 13.3–16.6 |
Brain metastases | |||
With | 21 | 11.1 | 8.5–14.3 |
Without | 144 | 15.3 | 13.3–17.4 |
Liver metastases | |||
With | 44 | 9.6 | 6.5–13.2 |
Without | 121 | 16.1 | 14.3–18.2 |
Conclusions
Final results of ORIENTAL showed in the largest to date, real-world-like Chinese ES-SCLC cohort that D+EP was effective and well tolerated, further supporting D+EP as 1L SoC in China.
Clinical trial identification
NCT04449861.
Editorial acknowledgement
Medical writing support for the development of the abstract, under the input and direction of the authors, was provided by Xiaowei Ning and Bo Lyu from Costello Medical Singapore and funded by AstraZeneca China.
Legal entity responsible for the study
AstraZeneca China.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract